The International Association for the Study of Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the Ninth Edition TNM Classification.

Lung cancer Lung cancer staging Non–small cell lung cancer Prognosis TNM classification

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
06 2022
Historique:
received: 30 12 2021
revised: 11 02 2022
accepted: 18 02 2022
pubmed: 13 3 2022
medline: 1 6 2022
entrez: 12 3 2022
Statut: ppublish

Résumé

Stage classification provides a consistent and concise nomenclature about the anatomic extent of the cancer. This is a fundamental cornerstone in the management of patients; it enables reporting results and facilitates comparing one treatment to another and judging how closely clinical trial results apply to an individual patient. A nomenclature must be relatively static; however, periodical refinement is needed to adjust to a changing landscape of clinical relevance. Changes must be well justified and thoughtfully developed to maintain the ability to communicate clearly and facilitate comparisons across time. For thoracic malignancies (lung, pleura, thymus, and esophagus), the International Association for the Study of Lung Cancer (IASLC) has leveraged its worldwide multidisciplinary reach, permitting a sophisticated approach to this process. Refinement of stage classification for the ninth edition of TNM is underway; this article describes the approach adopted by the IASLC Staging and Prognostic Factors Committee. Key guiding principles include the ability to maintain communication over time, a classification that discriminates homogeneous cohorts of tumors consistently across the world in multiple settings, treatment approaches, and patient characteristics, including clinical relevance and practical applicability. The IASLC has again assembled a large international database to permit multifaceted analysis. Providing confidence that the classification performs consistently in multiple settings, treatments, and patients requires consistent discrimination in multiple subset analyses. Although observed outcomes of patients in the 2011 to 2019 database are essential, considerations about how the classification will be used are also important to ensure clinical relevance and applicability. The strategy developed by the Staging and Prognostic Factors Committee is carefully designed to provide useful refinements to the stage classification of thoracic malignancies for the ninth edition of TNM classification of cancers.

Identifiants

pubmed: 35278692
pii: S1556-0864(22)00107-1
doi: 10.1016/j.jtho.2022.02.008
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

806-815

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Frank C Detterbeck (FC)

Department of Surgery, Yale University, New Haven, Connecticut. Electronic address: frank.detterbeck@yale.edu.

Katherine K Nishimura (KK)

Cancer Research and Biostatistics, Seattle, Washington.

Vanessa J Cilento (VJ)

Cancer Research and Biostatistics, Seattle, Washington.

Meredith Giuliani (M)

The Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Mirella Marino (M)

Department of Pathology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Regina Elena National Cancer Institute, Rome, Italy.

Raymond U Osarogiagbon (RU)

Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee.

Ramon Rami-Porta (R)

Thoracic Surgery Service, Hospital Universitari Mutua Terrassa, Terrassa, Spain; Lung Cancer Group, Network of Centers for Biomedical Research in Respiratory Diseases (CIBERES), Terrassa, Spain.

Valerie W Rusch (VW)

Thoracic Surgery Service, Sloan Kettering Cancer Center, New York, New York.

Hisao Asamura (H)

Division of Thoracic Surgery, School of Medicine, Keio University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH